CN105327405B - 用于治疗宫颈炎的载药支架及其制备方法 - Google Patents
用于治疗宫颈炎的载药支架及其制备方法 Download PDFInfo
- Publication number
- CN105327405B CN105327405B CN201510707832.1A CN201510707832A CN105327405B CN 105327405 B CN105327405 B CN 105327405B CN 201510707832 A CN201510707832 A CN 201510707832A CN 105327405 B CN105327405 B CN 105327405B
- Authority
- CN
- China
- Prior art keywords
- drug
- cervicitis
- stent
- microspheres
- loaded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了用于治疗宫颈炎的载药支架及其制备方法,该方法主要为将PLGA加入到二氯甲烷中,再加入一定量的NaCl和头孢曲松钠,通过均质机将混合物分散成均匀液体。然后把上述液体缓慢滴加到PVA溶液中,经过搅拌得到多孔且载有头孢曲松钠的微球,用去离子水冲洗后进行冻干,即得到干燥的载药微球。将微球置于圆柱状模具中,放于70℃的烘箱中保温3小时,得到最终的载药支架。因为PLGA的降解产物为乳酸和乙酸,对身体不会造成副作用,且支架降解的同时伴随着药物的释放,直接作用于炎症部位,对于宫颈炎的治疗有重要的意义。
Description
技术领域
本发明涉及宫颈炎修复药物材料的制备方法,具体涉及到用于治疗宫颈炎的载药支架及其制备方法。
背景技术
宫颈炎是一种常见的妇科疾病,因为子宫颈管粘膜上皮是单层柱状上皮,极易被感染,药物治疗特别是口服药物一般药物利用率较低,且药物不易到达此部位,加上涉及隐私等问题,一般不会得到及时治愈,慢慢发展成慢性子宫颈炎症。
PLGA是乳酸和羟基乙酸的聚合物,水解的最终产物是水和二氧化碳,中间产物乳酸也是体内正常糖代谢产物,所以该聚合物无毒、无刺激性,具有良好的生物相容性。基于PLGA上述性质,因此PLGA广泛用于微球、微囊、纳米粒等的制备。因此,本发明提供了用于治疗宫颈炎的载药支架。
发明内容
本发明的目的在于克服现有技术存在的上述不足,提供用于治疗宫颈炎的载药支架及其制备方法。
用于治疗宫颈炎的载药支架的制备方法,其包括下列步骤:
(1)将0.5~0.8g的PLGA溶于5~6ml二氯甲烷中;
(2)称取0.1~0.15gNaCl和0.1~0.15g头孢曲松钠混合,加入到步骤(1)得到的液体中,通过均质机,以4500~5000rpm的转速搅拌4~5min,使得物质均匀分散在液体中;
(3)称取2~2.5g的PVA溶解在200~220ml去离子水中;
(4)将步骤(2)最终得到的混合液体加入到步骤(3)得到的液体中,并以250~350rpm的转速搅拌,搅拌6~8h;
(5)搅拌结束后,将所得微球用去离子水清洗,然后进行冻干;
(6)冻干后,将干燥的微球装入到柱状模具内,在65~70℃烘箱内保温2~3h,保温结束后,得到所述载药支架。
进一步实施地,步骤(5)所述将所得微球用去离子水清洗的清洗次数为5~8次。
进一步实施地,步骤(5)所述冻干的时间为24~36h。
本发明还提供由所述制备方法制得的用于治疗宫颈炎的载药支架。因为PLGA的降解产物为乳酸和乙酸,对身体不会造成副作用,且支架降解的同时伴随着药物的释放,直接作用于炎症部位,对于宫颈炎的治疗有重要的意义。
与现有技术相比,本发明的优势在于:
1)PLGA降解产物对身体组织没有任何副作用,生物相容性好;
2)多孔微球使得孔隙率增多,更有利于药物的释放;
3)直接作用于炎症部位,提高药物的利用率;
4)持续的药物释放,药物释放时间长,优于口服用药。
附图说明
图1为不同温度下支架的孔隙率对比图;
图2为不同支架的药物释放曲线;
具体实施方式
下面结合实施例,对本发明的实施方式作进一步解释说明,但具体实施例并不对本发明做任何限定。
实施例1
1)将0.5g的PLGA溶于5ml二氯甲烷中;
2)称取0.1gNaCl和0.1g头孢曲松钠混合,加入到(1)液体中,通过均质机,以5000rpm的转速搅拌5min,使得物质均匀分散在液体中;
3)称取2g的PVA溶解在200ml去离子水中;
4)将(2)混合液体缓慢加入到(3)中,并以300rpm的转速搅拌,搅拌6h;
5)搅拌结束后,将所得微球用去离子水清洗5次,然后进行冻干,冻干时间为24h;
6)冻干后,将干燥的微球装入到柱状模具内,在50℃烘箱内保温3h,保温结束后,得到载药支架。
实施例2
1)将0.5g的PLGA溶于5ml二氯甲烷中;
2)称取0.1gNaCl和0.1g头孢曲松钠混合,加入到(1)液体中,通过均质机,以5000rpm的转速搅拌5min,使得物质均匀分散在液体中;
3)称取2g的PVA溶解在200ml去离子水中;
4)将(2)混合液体缓慢加入到(3)中,并以300rpm的转速搅拌,搅拌6h;
5)搅拌结束后,将微球用去离子水清洗5次,然后进行冻干,冻干时间为24h;
6)冻干后,将干燥的微球装入到柱状模具内,在70℃烘箱内保温3h,保温结束后,得到载药支架。
实施例3
1)将0.5g的PLGA溶于5ml二氯甲烷中;
2)称取0.1gNaCl和0.1g头孢曲松钠混合,加入到(1)液体中,通过均质机,以5000rpm的转速搅拌5min,使得物质均匀分散在液体中;
3)称取2g的PVA溶解在200ml去离子水中;
4)将(2)混合液体缓慢加入到(3)中,并以300rpm的转速搅拌,搅拌6h;
5)搅拌结束后,将微球用去离子水清洗5次,然后进行冻干,冻干时间为24h;
6)冻干后,将干燥的微球装入到柱状模具内,在90℃烘箱内保温3h,保温结束后,得到载药支架。
实施例4
支架孔隙率对比实验
每种支架取3个平行样,分别进行排酒精法测得支架的孔隙率。从表1中可以得到50℃时支架的孔隙率的平均值为38.3771%,70℃时支架的孔隙率的平均值为20.9916%,90℃时支架的孔隙率的平均值为9.7378%。从图1也可以看出,随着温度的升高,支架的孔隙率逐渐减小。
表1 不同温度下支架孔隙率数据
实施例5
药物释放对比试验
从图2中可以看出,50℃的支架孔隙率很大,对药品与体液的接触极为有利,但不免会有药物的突释现象,造成初始阶段药物的浓度迅速升高,对身体造成伤害。70℃时支架的药物突释现象发生减小,药物在整个释放阶段释放的较为均匀。90℃与70℃相比,前15天区别不明显,后15天可以看出,90℃的支架药物释放量明显减小。综上能够得出70℃时载药支架最为理想。
本发明基于PLGA具有良好的生物相容性,将其先制备成多孔微球,其原理为在制备过程中加入NaCl,通过NaCl的溶解使得微球中留有孔洞,再将微球通过加热的方式制备成支架,支架中球与球之间同样有孔隙的存在,进一步增大孔隙率,有利于药物的释放。载入的药物是头孢曲松钠,该药物直接作用于炎症部位,提高了药物的利用率,且药物在一定时间内持续释放。
Claims (4)
1.用于治疗宫颈炎的载药支架的制备方法,其特征在于,包括下列步骤:
(1)将0.5~0.8g的PLGA溶于5~6ml 二氯甲烷中;
(2)称取0.1~0.15gNaCl和0.1~0.15g头孢曲松钠混合,加入到步骤(1)得到的液体中,通过均质机,以4500~5000rpm的转速搅拌4~5min,使得物质均匀分散在液体中;
(3)称取2~2.5g的PVA溶解在200~220ml去离子水中;
(4)将步骤(2)最终得到的混合液体加入到步骤(3)得到的液体中,并以250~350rpm的转速搅拌,搅拌6~8h;
(5)搅拌结束后,将所得微球用去离子水清洗,然后进行冻干;
(6)冻干后,将干燥的微球装入到柱状模具内,在70℃烘箱内保温2~3h,保温结束后,得到所述载药支架。
2.根据权利要求1所述的用于治疗宫颈炎的载药支架的制备方法,其特征在于,步骤(5)所述将所得微球用去离子水清洗的清洗次数为5~8次。
3.根据权利要求1所述的用于治疗宫颈炎的载药支架的制备方法,其特征在于,步骤(5)所述冻干的时间为24~36h。
4.由权利要求1~3任一项所述制备方法制得的用于治疗宫颈炎的载药支架。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510707832.1A CN105327405B (zh) | 2015-10-23 | 2015-10-23 | 用于治疗宫颈炎的载药支架及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510707832.1A CN105327405B (zh) | 2015-10-23 | 2015-10-23 | 用于治疗宫颈炎的载药支架及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105327405A CN105327405A (zh) | 2016-02-17 |
| CN105327405B true CN105327405B (zh) | 2019-01-29 |
Family
ID=55278302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510707832.1A Active CN105327405B (zh) | 2015-10-23 | 2015-10-23 | 用于治疗宫颈炎的载药支架及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105327405B (zh) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420016D0 (en) * | 2004-09-09 | 2004-10-13 | Leuven K U Res & Dev | Controlled release oral delivery system |
| CN102143996A (zh) * | 2008-10-30 | 2011-08-03 | 大卫·刘 | 微球形多孔可生物相容支架及制造该支架的方法和装置 |
| DK2872117T3 (en) * | 2012-07-16 | 2018-01-08 | Laccure Ab | PHARMACEUTICAL COMPOSITIONS CONTAINING OLIGOMS Lactic Acid |
| CN103212116A (zh) * | 2013-04-19 | 2013-07-24 | 华南理工大学 | 一种由plga/碳酸钙多孔复合微球构建三维支架的方法 |
-
2015
- 2015-10-23 CN CN201510707832.1A patent/CN105327405B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105327405A (zh) | 2016-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10584183B2 (en) | Method for producing hydrogels coupling high elastic modulus and absorbance | |
| CN1745745A (zh) | 一种植物多糖空心胶囊原料组合物及空心胶囊的制备方法 | |
| CN101854929A (zh) | 新型制剂 | |
| CN105188668B (zh) | 基于低分子量甲基纤维素的肠胃外药物递送系统 | |
| CN107233301B (zh) | 一种纳米颗粒凝胶载药系统的快速制备方法 | |
| CN105169366B (zh) | 一种醋酸曲普瑞林缓释微球的制备方法 | |
| Iswandana et al. | Preparation of calcium alginate-tetrandrine beads using ionic gelation method as colon-targeted dosage form | |
| CN112004528A (zh) | 载药微珠组合物、栓塞组合物和相关方法 | |
| CN104288093B (zh) | 纳米药物透皮制剂在肿瘤中的应用 | |
| CN110327310A (zh) | 一种多核共壳复合载药微球及其制备方法和应用 | |
| CN107405307A (zh) | 一种艾塞那肽微球制剂及其制备方法 | |
| CN117530933A (zh) | 一种吡仑帕奈长效缓释微球、制备方法及缓释注射剂 | |
| CN105327405B (zh) | 用于治疗宫颈炎的载药支架及其制备方法 | |
| CN104740641B (zh) | 一种糖敏感的缓控释微球组合物及其制备方法 | |
| CN116421874A (zh) | 一种载抗血管瘤药物可溶微针贴片及其制备方法 | |
| CN101204382A (zh) | 植入型抗肿瘤药丝裂霉素双重缓释膜剂及其制备方法 | |
| CN103877625B (zh) | 一种栓塞用plga/白芨复合微球及其制备方法 | |
| KR20100097075A (ko) | 소수성 및 친수성 약물 전달용 유비쿼터스 주입형 온도감응성 겔 | |
| KR20170109221A (ko) | 저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템 | |
| CN106178084A (zh) | 一种载药聚乳酸手术缝合线的制备方法 | |
| CN101249082B (zh) | 枸橼酸他莫昔芬聚乳酸-羟乙酸共聚物微球的制备方法 | |
| CN108113976A (zh) | Th-302制剂、制备方法及其用途 | |
| CN100562322C (zh) | 一种5-氨基水杨酸的结肠靶向制剂及其制备方法 | |
| CN108514546B (zh) | 一种二氢杨梅素的壳聚糖水凝胶制剂及制备方法 | |
| CN115068674A (zh) | 功能性水凝胶敷料及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |